Pfizer Inc
Close on Nov 2, 2026Market cap $174.81BP/E 43.8Yield 5.61%
Pfizer Total Biopharma Royalty Revenues by Year
Total Biopharma Royalty Revenues (cross-portfolio summary) — International revenues ($M) ($M)
Pfizer Total Biopharma Royalty Revenues: $11M in FY2025, up 83.3% from a year earlier.
Where the FY2025 figure comes from
“|| Total Royalty revenues included above | $ | 1,650 | $ | 1,423 | 16% | 16% | $ | 1,639 | $ | 1,418 | 16% | $ | 11 | $ | 6 | 94% | 91%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Biopharma Royalty Revenues (cross-portfolio summary) — International revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11 | +83.3% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 6 | – | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
Breakdown
What makes up total Biopharma Royalty Revenues
Cite this data
StockData. (2026). Pfizer Total Biopharma Royalty Revenues ($M), annual FY2024–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/royalty-rev-intl
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.
See a number that looks wrong?